|

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

RECRUITINGPhase 2Sponsored by University of Texas Southwestern Medical Center
Actively Recruiting
PhasePhase 2
SponsorUniversity of Texas Southwestern Medical Center
Started2025-04-01
Est. completion2027-10
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06601296

Summary

To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients must have metastatic ccRCC.
* Patients must have oligoprogression defined as progression in ≤5 lesions.
* All oligoprogression lesions must be suitable for radiation.
* Patients must have at least one site of disease that can be safely injected with IMSA101.
* Karnofsky Performance Status (KPS) of at least 50%.
* Age ≥ 18 years.
* Patients must have adequate organ and marrow function within 14 days prior to study entry.
* All IMDC risk categories are allowed.

Exclusion Criteria:

* Patients with progressive ultracentral/central chest lesions will be excluded

Conditions3

CancerMetastatic Renal Cell Carcinoma (mRCC)OligoProgressive Metastatic Disease

Locations1 site

University of Texas Southwestern Medical Center
Dallas, Texas, 75390
BUSAYO ADEFALUJO, CLINICAL RESEARCH COORDINATOR214 648 1873Busayo.Adefalujo@UTSouthwestern.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.